This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Boldenone Undecylenate

Well Researched

Veterinary-equine AAS — testosterone with an added 1,2-double bond, esterified to undecylenate for ~14-day half-life.

Aliases (13)

Equipoise · EQ · BU · boldenone · boldenone undecanoate · 1-dehydrotestosterone undecylenate · Δ1-testosterone undecylenate · Ganabol · Vebonol · Boldebal-H · Equigan · Sybolin · Ultragan

TYPICAL DOSE

Veterinary equine: ~1 mg/kg every 2-3 weeks (Eq…

Weekly

ROUTE

Intramuscular injection (oil)

Intramuscular

CYCLE

12-16 weeks for the long undecylenate ester

Cycle length (8-16 wk)

STORAGE

Room temp; protect from light

Room temp

Overview

What is Boldenone Undecylenate?

Boldenone (Equipoise, EQ) is a synthetic anabolic-androgenic steroid (AAS), structurally a 1-dehydro analog of testosterone. Originally a veterinary product for horses, it is widely used by bodybuilders and is a Schedule III controlled substance in the US.

Key Benefits

Slow, lean, vascular muscle gain over long cycles, increased red blood cell production (notable "pump" and endurance), modest androgenic side-effect profile relative to mass gained, and increased appetite.

Mechanism of Action

Androgen receptor agonist with an anabolic:androgenic ratio of ~100:50. Aromatizes to a small extent (less than testosterone) and increases erythropoietin output, raising hemoglobin and hematocrit.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸ Vial inspection & sterile draw AAS oil

AAS oil arrives pre-suspended in carrier oil — no BAC water needed. Inspect for clarity, color, and crashed compound (cold storage can crystallize). Warm vial in palm or under hot tap before draw.

Steps

1 Wipe vial stopper with isopropyl alcohol.
2 Warm vial 30-60s in palm if oil is cold/cloudy.
3 Draw with 18g needle into 22-25g pin barrel for IM, or 27-29g for sub-Q.
4 Tap out air bubbles, expel a small drop, then inject at chosen site.

Open dose calculator for Boldenone Undecylenate

▸ Cycle structure & PCT AAS

Ester

enanthate

Cycle

12-16 week

Frequency

weekly

PCT

Required

Phase 1 — On cycle

Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.

Phase 2 — Bridge / cease

On the last dose, the ester clears over its half-life window (enanthate = est. 7 days). PCT begins after the active compound has cleared.

Phase 3 — PCT (post-cycle therapy)

Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).

Research Indications

Most Effective

Lipophilic

slow release from intramuscular oil depot

Effective

Long-acting

terminal half-life ~14 days; clinical effect persists 2-3+ weeks per dose

Investigational

Slow-onset

peak serum levels at 3-4 days post-injection, full steady-state takes 4-6 weeks of weekly dosing

Peptide Interactions

(For appropriate populations only — i.e., NOT this-archetype at 20)

Synergistic

[testosterone-enanthate](testosterone-enanthate.md): Standard "TRT base" companion to any AAS cycle. Provides the testosterone the user no longer makes endog…

[methenolone](methenolone.md) (Primobolan):

Synergistic

"Quality lean" stacking partner — both mild AAS, both non-alkylated, both relatively HPG-friendly within the class. Common Tier-2 cycle composition.

Aromatase inhibitor (anastrozole, letrozole):

Synergistic

Standard estrogen-management adjunct; titrated against E2 sensitive-assay levels.

HCG (250-500 IU 2× weekly during cycle):

Synergistic

Maintains testicular volume / responsiveness; often used to ease PCT. Not a substitute for PCT.

[trenbolone](trenbolone.md):

Avoid

Combined polycythemia, BP elevation, lipid disturbance, and cardiac stress profile. Tren+EQ stacks are common in advanced bodybuilding but represent a substa…

Other strong erythropoietic AAS:

Avoid

Stacking EQ with anything else that strongly elevates RBC mass (e.g., high-dose testosterone, nandrolone) compounds polycythemia risk.

17α-alkylated orals (dianabol, anavar, winstrol):

Avoid

Hepatotoxicity stacking; cumulative liver burden during multi-month cycles.

NSAIDs (chronic):

Avoid

BP / kidney load stacking with the BP-elevating effect of EQ.

Quality Indicators

✓

White, fluffy cake (peptides)

Lyophilized peptide should appear as a white, fluffy "cake" filling most of the vial bottom. Indicates proper freeze-drying.

✓

Clear solution after reconstitution

After mixing with bacteriostatic water, the solution should be crystal clear with no particles or cloudiness.

Slight clumping acceptable

Small clumps that fully dissolve with gentle swirling are normal — shipping can cause minor compaction.

✗

Collapsed or melted powder

Powder that looks collapsed, melted, or stuck to vial sides may have been heat-damaged in transit.

✗

Cloudy or particulate solution

Persistent cloudiness or visible particles after gentle mixing indicate degraded or contaminated material.

What to Expect

Onset
Slow. Even with frontloading, most users describe nothing meaningful until week 4-6. Full effect at week 8-12.
Peak
effect: Lean mass accrual (slow), increased vascularity, mild-to-moderate appetite stimulation, libido elevation, mild RBC-driven endurance improvement.

Side Effects & Safety

Common (>10% in user-population observation):
- Polycythemia / elevated hematocrit (signature side effect). Hematocrit can climb from baseline 42-46% to 55%+ at typical doses. Therapeutic phlebotomy may be needed; some clinicians treat hematocrit >54% as a hard threshold for dose reduction or cycle termination.
- HPG-axis suppression. Total T suppressed to single-digit ng/dL within 4-8 weeks. LH/FSH suppressed below detection limit. Recovery 12-24 weeks post-PCT for first cycle in healthy young adults; longer with stacking, age, prior cycles. Permanent HPG dysfunction / hypogonadism is a real outcome for users who cycle aggressively at young ages or fail to PCT.
- Lipid disturbance. HDL-C suppression (often −40 to −60% from baseline), LDL-C and ApoB elevation, oxLDL elevation. Class-wide AAS effect; boldenone's milder vs. orally-bioavailable AAS but still clinically meaningful. Cardiovascular risk integral over years of cycling is the single most quantified long-term harm of AAS use.
- Blood pressure elevation. Both from RBC-mass-driven volume effect and direct AR effects on vascular tone. 24-hr ambulatory BP often shifts +10-15 mmHg systolic on cycle.
- Acne, oily skin. DHT-pathway side effect; less than testosterone but present.
- Increased libido. Generally reported; can be excessive at higher doses.
Less common (1-10%):
- Anxiety. Persistent community report; mechanism uncertain.
- Hair loss / androgenic alopecia. In genetically predisposed individuals; less aggressive than testosterone but possible.
- Gynecomastia. From estrogen elevation (boldenone aromatizes to 1-dehydroestradiol). Less common than on testosterone but real; aromatase inhibitor (anastrozole 0.25-0.5 mg E2D, or letrozole 0.5 mg 2-3×/week) often used as adjunct.
- Sleep apnea exacerbation. RBC mass + BP + neck soft-tissue effects can worsen pre-existing sleep apnea; relevant for stocky-build athletes.
- Mild ALT/AST elevation. Modest, reversible.
Rare-serious (<1% but worth knowing):
- Thrombotic events. Polycythemia + lipid changes + BP elevation drive a measurable VTE / MI / stroke risk. Case reports document MI in users <30; absolute incidence is low but real and dose-dependent.
- Cardiomyopathy. AAS-induced cardiomyopathy (left ventricular hypertrophy, diastolic dysfunction, fibrosis) is documented in long-term users. Echocardiographic findings often persist after discontinuation. Not boldenone-specific — class-wide.
- Sudden cardiac death. Documented in AAS-user case series; absolute rates low but materially elevated vs. age-matched non-users.
- Permanent HPG suppression / infertility. Documented in users who cycle aggressively at young ages.
- Hepatic peliosis / cholestatic jaundice: Rare for non-17α-alkylated AAS like boldenone; much higher risk for orals.
- Veterinary product contamination. Counterfeit / underdosed / over-dosed product is documented; bacterial contamination of injectable oils from inadequately sterilized underground labs has produced abscesses and systemic infections.
Specific watch periods:
- Weeks 4-8: hematocrit, BP, lipids — first wave of changes
- Weeks 8-12: estradiol management, gynecomastia surveillance, peak HPG suppression
- Post-cycle weeks 4-12: PCT, HPG recovery, lipid normalization
- Post-cycle months 6-12: sperm analysis if fertility-relevant
Combat-sport / archetype-specific risks:
- Polycythemia + cardio-load. Combat sports require sustained cardiovascular output. Hematocrit 55+% adds blood viscosity, raises BP under load, and may impair cardiac output during high-intensity rounds. Training with elevated hematocrit is a real cardiac-event risk amplifier.
- HPG suppression at 20. Permanent-fertility risk; permanent-HPG-axis-injury risk; suppressed natural T affects mood, sleep, and recovery for months post-cycle.
- Brain-priority conflict. No documented cognitive benefit; possible cognitive cost from polycythemia-driven viscosity. Direct conflict with brain-priority stack.
- WADA prohibition. S1.1a banned; long detection window (5-12 months urine) precludes any pivot to sanctioned competition for a year+.